These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25948101)

  • 41. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
    Ginsberg L; Katic A; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Adler LA
    Curr Med Res Opin; 2011 Jun; 27(6):1097-107. PubMed ID: 21438796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
    Biederman J; Pliszka SR
    J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dasotraline in ADHD: novel or me too drug?
    Vandana P; Arnold E
    Expert Rev Neurother; 2019 Apr; 19(4):311-315. PubMed ID: 30871381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment.
    Wigal T; Childress A; Frick G; Yan B; Wigal S; Madhoo M
    Postgrad Med; 2018 Jan; 130(1):111-121. PubMed ID: 29087231
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study.
    Ginsberg Y; Arngrim T; Philipsen A; Gandhi P; Chen CW; Kumar V; Huss M
    CNS Drugs; 2014 Oct; 28(10):951-62. PubMed ID: 25183661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial.
    Grilo CM; McElroy SL; Hudson JI; Tsai J; Navia B; Goldman R; Deng L; Kent J; Loebel A
    CNS Spectr; 2021 Oct; 26(5):481-490. PubMed ID: 32423512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.
    Weisler R; Young J; Mattingly G; Gao J; Squires L; Adler L;
    CNS Spectr; 2009 Oct; 14(10):573-85. PubMed ID: 20095369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-Hoc Analyses of the Effects of Baseline Sleep Quality on SHP465 Mixed Amphetamine Salts Extended-Release Treatment Response in Adults with Attention-Deficit/Hyperactivity Disorder.
    Surman CBH; Robertson B; Chen J; Cortese S
    CNS Drugs; 2019 Jul; 33(7):695-706. PubMed ID: 31228031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
    Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.
    Lin DY; Kratochvil CJ; Xu W; Jin L; D'Souza DN; Kielbasa W; Allen AJ
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):190-200. PubMed ID: 24840045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
    Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
    Brown TE; Brams M; Gao J; Gasior M; Childress A
    Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study.
    Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
    BMC Psychiatry; 2020 Oct; 20(1):485. PubMed ID: 33008345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
    Jain R; Segal S; Kollins SH; Khayrallah M
    J Am Acad Child Adolesc Psychiatry; 2011 Feb; 50(2):171-9. PubMed ID: 21241954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.